Kura Oncology (NASDAQ:KURA) Given “Market Outperform” Rating at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $28.00 price target on the stock.

A number of other research analysts have also recently commented on the company. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Bank of America reduced their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, UBS Group initiated coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Trading Down 2.5 %

NASDAQ KURA opened at $8.82 on Thursday. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The business has a 50 day simple moving average of $8.79 and a two-hundred day simple moving average of $15.11. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the prior year, the business posted ($0.50) earnings per share. On average, sell-side analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 12,255 shares of company stock valued at $100,739. Corporate insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new stake in Kura Oncology in the third quarter worth about $25,000. Point72 DIFC Ltd purchased a new position in shares of Kura Oncology in the 3rd quarter valued at approximately $146,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology in the 4th quarter worth approximately $90,000. Erste Asset Management GmbH purchased a new stake in Kura Oncology during the 3rd quarter worth approximately $215,000. Finally, Bellevue Group AG increased its stake in Kura Oncology by 36.0% during the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after purchasing an additional 3,600 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.